Mycobacterial antigen composition
View Patent ↗The present invention provides an antigenic composition for use as a mycobacterial vaccine, said composition comprising (i) a first mycobacterial antigenic polypeptide, wherein said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, or a fragment thereof having at least 50 consecutive amino acids thereof; or (ii) a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide, or wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence selected from SEQ ID NO: 5, 11, 1, 17, 7, 9, 15, 3.
1. An antigenic composition comprising a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence having at least 90% identity to SEQ ID NO: 7 or a fragment thereof having at least 450 consecutive nucleotides thereof;
wherein said antigenic composition induces an immune response in a subject; and wherein
A) said antigenic composition comprises at least one vector and wherein said mycobacterial polynucleotide is incorporated into said at least one vector; wherein said vector is an expression vector, or a viral vector, or a plasmid; or
B) said antigenic composition comprises an immunologically useful adjuvant.
2. The antigenic composition according to claim 1 , further comprising at least one additional (second) mycobacterial polynucleotide encoding a second mycobacterial antigenic polypeptide, wherein said second mycobacterial polypeptide is different from said first mycobacterial polypeptide.
3. The antigenic composition according to claim 1 , wherein said antigenic composition comprises at least one vector and wherein said mycobacterial polynucleotide(s) is/are incorporated into said at least one vector.
4. The antigenic composition according to claim 3 , wherein said vector is an expression vector or a viral vector.
5. The antigenic composition of claim 3 , wherein said vector is a plasmid.
6. The antigenic composition according to claim 1 , wherein said antigenic composition comprises at least one cell, and wherein said cell comprises at least one of said mycobacterial polynucleotides.
7. The antigenic composition of claim 6 , wherein said cell is an attenuated microbial carrier.
8. The antigenic composition of claim 7 , wherein said attenuated microbial carrier is attenuated salmonella , attenuated M. bovis or attenuated M. tuberculosis.
9. The antigenic composition of claim 8 , wherein said attenuated M. bovis is a BCG strain of M. bovis.
10. The antigenic composition of claim 1 , wherein said viral vector is an attenuated vaccinia virus vector or an adenoviral vector.